IL17A and psoriasis: A network meta-analysis has demonstrated that the efficacy of deucravacitinib in treating psoriasis is comparable to TNF-α inhibitors and IL-12/23 inhibitors, but lower than the more recent biologics of IL-17 inhibitors and IL-23 inhibitors [19].